MG
HZNP

Mather Group’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Mather Group’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2,828
Closed -$327K – 580
2023
Q3 		$327K Hold
2,828
– – 0.01% 423
2023
Q2 		$291K Buy
2,828
+69
+3% +$7.28K ﹤0.01% 464
2023
Q1 		$301K Hold
2,759
– – 0.01% 395
2022
Q4 		$314K Buy
+2,759
New +$229K 0.01% 380
2022
Q2 		– Sell
-5,659
Closed -$595K – 485
2022
Q1 		$595K Sell
5,659
-928
-14% -$90.4K 0.01% 234
2021
Q4 		$710K Buy
+6,587
New +$719K 0.01% 185

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.05B AUM 19.75% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Mather Group's HZNP Position: Q4 2023 in Review

Mather Group sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 2,828 shares — an estimated $327K sold.

Mather Group first reported a position in HZNP in Q4 2021 and held it in 6 quarters. The position peaked at $710K in Q4 2021. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Mather Group reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Mather Group sold 2,828 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $327K.
  • Mather Group first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2021 and held it in 6 quarters.
  • Mather Group's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $710K in Q4 2021.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Mather Group's 13F filing for Q4 2023, filed 5 Feb 2024.